T-Cell Therapy for Advanced Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

186 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test the safety of different doses of specially prepared T cells collected from the blood. The investigators want to find a safe dose of these modified T cells for patients who have metastatic HER2-negative breast cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer

NCT01022138

Breast Cancer

TERMINATED PHASE2

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer

NCT00429182

Breast Cancer Metastatic Breast Carcinoma Invasive Breast Carcinoma

COMPLETED PHASE2

Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2

NCT00019812

Breast Cancer

COMPLETED PHASE2

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

NCT05378464

HER2-positive Breast Cancer

RECRUITING PHASE1

Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer

NCT01219907

HER2-positive Breast Cancer Male Breast Cancer Stage IV Breast Cancer

WITHDRAWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Metastatic HER2-negative Breast

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

T-cell infusion

A single blood volume leukapheresis for harvesting of PBMCs will be performed, As the transduced T cells will be frozen, the timing of leukapheresis is not defined \& can vary from patient to patient. Subsequently, a single dose of mesothelin-targeted T cells will be infused via intravenous catheter or central line (i.e., mediport). Patients will be monitored in the hospital and discharged home after a minimum of 48 hours. Patients will be monitored closely as outpatients for the next 2 months. Patients will be followed weekly as outpatients for the first 8 weeks after treatment. All patients will be hydrated intravenously, premedicated with acetaminophen \& diphenhydramine, \& administered cyclophosphamide at 1.5 g/m2 2 to 7 days (Day -7 to Day -2) before administration of mesothelin-targeted T cells.

Group Type EXPERIMENTAL

Cyclophosphamide

Intervention Type DRUG

Mesothelin-targeted T cells

Intervention Type BIOLOGICAL

AP1903

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cyclophosphamide

Intervention Type DRUG

Mesothelin-targeted T cells

Intervention Type BIOLOGICAL

AP1903

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged ≥18 years with metastatic breast cancer
* Karnofsky performance status ≥70%
* Patients with breast cancer that is pathologically confirmed at MSKCC (pathology from outside institutions is acceptable for the screening phase of the protocol) and defined by the following:

* HER2 negative (in cases of mixed HER2 results, the most recent pathology results considered reflective of the active cancer will be considered)
* Previously treated with at least 1 chemotherapy regimen for metastatic disease and documented progression
* Expression of mesothelin must be confirmed by meeting 1 of the following criteria:

* Mesothelin expression (\>10% of the tumor expressing mesothelin) by IHC
* Elevated serum SMRP levels (\>1.0 nM/L)
* Presence of measurable or evaluable disease
* Chemotherapy, targeted therapy (such as a tyrosine kinase inhibitor), or radiotherapy must have been completed at least 14 days before administration of T-cells. Prior immunotherapy with checkpoint blockade (i.e., PD1 inhibitor, PDL1 inhibitor, or CTL4-antagonist or similar agent) must have been completed more than 1 month before the T-cell infusion.

\*Chemotherapy must have been completed at least 7 days prior to leukapheresis
* Any major operation must have occurred at least 28 days before study enrollment.
* All acute toxic effects of any previous radiotherapy, chemotherapy, or surgical procedures must have resolved to grade 1 or lower according to CTCAE
* Lab requirements (hematology):

* White blood cell (WBC) count ≥3000 cells/mm\^3
* Absolute neutrophil count ≥1500 neutrophils/mm\^3
* Platelet count ≥100,000 platelets/mm\^3
* Lab requirements (serum chemistry):

* Bilirubin \<1.5x upper limit of normal (ULN)
* Serum alanine aminotransferase/serum aspartate aminotransferase (ALT/AST) \<5x ULN
* Serum creatinine \<1.5x ULN or Cr \>1.5x ULN, but calculated clearances of \>60
* Negative screen for human immunodeficiency virus (HIV), hepatitis B virus (HBV) antigen, and hepatitis C virus (HCV). If testing was performed during the previous 3 months, there is no need to repeat testing, as long as documentation of results is provided to the study site. Subjects must receive counseling and sign a separate informed consent form for HIV testing.
* Subjects and their partners with reproductive potential must agree to use an effective form of contraception during the period of drug administration and for 4 weeks after completion of the last administration of the study drug. An effective form of contraception is defined as oral contraceptives plus 1 form of barrier or double-barrier method contraception (condom with spermicide or condom with diaphragm).
* Subjects must be able to understand the potential risks and benefits of the study and must be able to read and provide written, informed consent for the study.
* Availability of archival tumor tissues (FFPE tissue block or 10-15 unstained slides)

Exclusion Criteria

* Untreated or active CNS metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control); patients with a history of treated CNS metastases are eligible, provided that all of the following criteria are met:

* Presence of measurable or evaluable disease outside of the CNS;
* Radiographic demonstration of improvement upon completion of CNS- directed therapy and no evidence of interim progression between completion of CNS-directed therapy and the screening radiographic study;
* Completion of radiotherapy ≥8 weeks prior to the screening radiographic study;
* Discontinuation of corticosteroids and anticonvulsants ≥4 weeks prior to the screening radiographic study.
* History of seizure disorder
* Patients currently receiving treatment for concurrent active malignancy. Prior immunotherapy with checkpoint blockade (i.e., PD1 inhibitor, PDL1 inhibitor, or CTL4-antagonist or similar agent) must have been completed more than 1 month prior to the T-cell infusion.
* Autoimmune or antibody-mediated disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, Crohn's disease, and temporal arteritis (patients with a history of hypothyroidism will not be excluded)
* Clinically significant cardiac disease (New York Heart Association class III/IV) or severe debilitating pulmonary disease
* Pregnant or lactating women
* Known active infection requiring antibiotics within 7 days of the start of treatment (Day 0)
* A requirement for daily systemic corticosteroids for any reason or a requirement for other immunosuppressive or immunomodulatory agents. Topical, nasal, and inhaled steroids are permitted.
* Administration of live, attenuated vaccine within 8 weeks before the start of treatment (Day 0) and throughout the study
* Any other medical condition that, in the opinion of the PI, may interfere with a subject's participation in or compliance with the study
* Participation in a therapeutic research study or receipt of an investigational drug within 30 days of T-cell infusion

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No